Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ishares Msci Spain ETF (EWP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ishares Msci Spain ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Ishares Msci Spain ETF trades at $59.8. The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWP | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $60.28 |
52-Week Low | $278.09 | $43.48 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWP is trading at $59.45, up 0.47% on the day, with a bullish technical signal driven by moving averages. The stock shows neutral momentum oscillators. A dividend of $0.92 is scheduled for payment on June 18, 2026. Recent European market strength, including record highs for the STOXX 600, provides a supportive regional backdrop.
The outlook is cautiously optimistic, supported by technical strength and positive European equity trends. Key risks include sensitivity to ECB interest rate decisions and broader macroeconomic pressures from energy price volatility. The dividend payment offers a potential income component for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →
